Exploring the Link Between Hyperuricemia and Cardiovascular Disease: What You Need to Know. Uric Acid Causes Atrial Fibrillation and Kidney Failure

Uric Acid is a destructive chemical waste product that causes atrial fibrillation — Uric Acid is a Metabolic Waste Product that Causes Remarkable Damage, even in Modest Levels in Your Blood

For decades, elevated serum uric acid (SUA) was primarily associated with gout and nephrolithiasis. However, mounting evidence has reframed hyperuricemia as a pathophysiological contributor to a broader array of diseases, particularly those involving the cardiovascular and renal systems. Elevated SUA is now implicated in the pathogenesis and progression of atherosclerosis, hypertension, heart failure, atrial fibrillation (AF), aneurysmal disease, and chronic kidney disease (CKD). This blog explores the emerging literature linking hyperuricemia with four major complications: heart disease, aneurysms, atrial fibrillation, and kidney failure.

1. Uric Acid as a Vascular Toxin

Uric acid, the final oxidation product of purine metabolism, is pro-oxidant under physiological conditions. It enters endothelial and vascular smooth muscle cells via specific transporters (e.g., URAT1, GLUT9), where it triggers intracellular oxidative stress, reduces nitric oxide bioavailability, and induces inflammation via NF-κB activation. These events collectively promote endothelial dysfunction, a precursor to most forms of cardiovascular pathology.

2. Uric Acid and Atherosclerotic Heart Disease, Atrial Fibrillation and Valvular disease.

Elevated SUA correlates with increased risk of ischemic heart disease, independent of classical risk factors. The pathophysiologic mechanisms include vascular smooth muscle proliferation, foam cell formation, and heightened platelet aggregation. Moreover, uric acid has been shown to promote coronary artery calcification and arterial stiffness.

In a large prospective cohort study, hyperuricemia was found to be a predictive marker of myocardial infarction and cardiovascular mortality, even among individuals with normal renal function and without gout.

3. Uric Acid and Aneurysm Formation

Uric acid causes atrial fibrillation, chronic kidney failure and aortic aneurysm

Hyperuricemia has been associated with abdominal aortic aneurysms (AAAs) through mechanisms involving matrix metalloproteinase activation, increased oxidative stress, and vascular inflammation. Animal studies demonstrate that uric acid exacerbates elastin degradation and adventitial inflammation in the aortic wall, accelerating aneurysmal dilation. Clinically, higher uric acid levels have been reported in patients with AAA compared to matched controls, suggesting a biomarker or mechanistic role.

4. Uric Acid and Atrial Fibrillation

There is increasing recognition that elevated SUA is an independent risk factor for atrial fibrillation, especially in the elderly. Uric acid contributes to atrial remodeling by enhancing oxidative injury, promoting fibrosis via TGF-β signaling, and stimulating atrial myocyte apoptosis. Large epidemiological studies, including the Framingham Heart Study, have shown a dose-dependent relationship between SUA and incident AF, even after adjusting for renal function, hypertension, and metabolic syndrome.

5. Uric Acid and Chronic Kidney Disease (CKD)

The kidney is both the source and the target of uric acid’s pathogenicity. Uric acid induces afferent arteriolar vasoconstriction, glomerular hypertension, and tubulointerstitial fibrosis. It also inhibits endothelial nitric oxide synthase, worsening renal perfusion. Longitudinal studies have shown that hyperuricemia is not merely a marker but a causal mediator of CKD progression. Uric acid-lowering therapy has been shown to slow eGFR decline in multiple interventional trials.

6. Therapeutic Implications

While the use of uric acid-lowering therapy (ULT) such as allopurinol or febuxostat has been traditionally confined to gout management, emerging trials suggest pleiotropic benefits in cardiovascular and renal outcomes. The FEATHER and FREED studies demonstrated renal protection in hyperuricemic patients with CKD stages 3–4, while the CARES trial illuminated the cardiovascular risk-benefit profile of febuxostat.

Dietary interventions (low-purine, reduced fructose intake), weight loss, and pharmacologic ULT may serve as effective strategies to modulate serum uric acid and reduce downstream morbidity.

Conclusion

Uric acid is no longer a passive metabolic byproduct but an active player in cardiovascular and renal disease pathogenesis. Screening for and addressing hyperuricemia—particularly in patients with comorbid hypertension, CKD, or metabolic syndrome—may represent an underutilized strategy in risk mitigation. Given the accumulating evidence, it is prudent to view uric acid not just as a marker but as a modifiable risk factor for systemic disease.

Controlling this problem is as easy as taking a single Allopurinol tablet per day, Uloric tablet, or using the over the counter product, Uric Acid Balance.

At the very least, get your uric acid level checked when you get your routine blood work.

More to come. I will be doing a post on the relationship between Uric Acid and Atrial Fibrillation in greater detail. This is a game-changer.

Natural treatment of elevated uric acid — An over the counter alternative to Allopurinol and/or Uloric prescription

References

Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821.
Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11.
Kuwabara M, Niwa K, Nishi Y, et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014;37(8):785–789.
Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001;87(12):1411–1414.
Zhang W, Iso H, Ohira T, et al. Serum uric acid and risk of cardiovascular mortality: the Japan Collaborative Cohort Study. J Atheroscler Thromb. 2016;23(8):692–703.
Kivity S, Kopel E, Maor E, et al. Association of serum uric acid and cardiovascular disease: a 20-year follow-up study. J Clin Hypertens. 2013;15(1):51–57.
Battelli MG, Bortolotti M, Polito L, et al. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim Biophys Acta. 2015;1851(1):96–104.
Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang D-H. Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234–1242.
Wen Y, Xu J, Ma X, et al. Serum uric acid levels and the prevalence of abdominal aortic aneurysm in Chinese patients. Clin Chim Acta. 2018;482:100–105.
Domienik-Karłowicz J, Stępień A, Rostoff P, et al. Serum uric acid levels and abdominal aortic aneurysm expansion. Angiology. 2022;73(2):174–180.
Tamariz L, Agarwal S, Soliman EZ, et al. Uric acid as a predictor of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm. 2011;8(8):1160–1166.
Kuwabara M, Niwa K, Ohtahara A, et al. Hyperuricemia is an independent risk factor for atrial fibrillation in Japanese hypertensive patients. Hypertens Res. 2012;35(6):739–743.
Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150–163.
Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99(11):759–766.
Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407–2413.
Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134–146.
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51–59.
Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885–892.
Kojima S, Sakamoto T, Ishihara M, et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol. 2005;96(4):489–495.
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–1210.